Evaxion biotech a/sEVAX.US Overview

US StockHealthcare

(No presentation for EVAX)

Overview AI Analysis AI Earnings Summary Financials Financial Forecast Stock Sentimental Institutions TradingView Chart

EVAX Overall Performance

EVAX AI Analysis & Strategy

EVAX Recent Performance

-0.58%

Evaxion biotech a/s

0.81%

Avg of Sector

-1.14%

S&P500

EVAX PowerScanner

EVAX Key Information

EVAX Valuation Metrics

EVAX Earnings Table

EVAX Profile

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.